Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 134 Carcinoma, Non-Small-Cell Lung 133 Prostatic Neoplasms 87 Lung Neoplasms 43 Neoplasms 31 Squamous Cell Carcinoma of Head and Neck 30 Neoplasm Metastasis 29 Stomach Neoplasms 26 Head and Neck Neoplasms 24 Esophageal Neoplasms 20 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Pancreatic Neoplasms 17 Ovarian Neoplasms 16 Urinary Bladder Neoplasms 13 Sarcoma 12 Adenocarcinoma of Lung 9 Triple Negative Breast Neoplasms 8 Fallopian Tube Neoplasms 8 Carcinoma, Transitional Cell 8 Carcinoma, Ovarian Epithelial 8 Adenocarcinoma Of Esophagus 7 Recurrence 6 Inflammatory Breast Neoplasms 5 Carcinoma, Squamous Cell 5 Carcinoma 5 Breast Neoplasms, Male 5 Adenocarcinoma, Bronchiolo-Alveolar 5 Laryngeal Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Advanced Solid Tumors 4

Interventions

pegfilgrastim 4 balugrastim 2 NPI 2358 2 Granulocyte Colony-Stimulating Factor 2 Drug Therapy 2 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Chemotherapy-induced Neutropenia × Docetaxel × Clear all

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡